Pfizer
NEWS
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
Under the terms of the deal, Pfizer is picking up all outstanding shares of Trillium that it doesn’t already own for $18.50 per share in cash.
It was another busy week in clinical trial news. Here’s a look.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
JOBS
IN THE PRESS